Pfizer's Lung Cancer Treatment Sigvotatug Vedotin Falls Short in Phase 3 Trial

SentiSense · Published · Updated

Pfizer's lung cancer treatment sigvotatug vedotin has failed to meet its primary goal in a phase 3 trial for previously treated metastatic lung cancer...

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis